|
1
|
Nordenstedt H, White DL and El-Serag HB:
The changing pattern of epidemiology in hepatocellular carcinoma.
Dig Liver Dis. 42(Suppl 3): S206–S214. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Clavien PA, Petrowsky H, DeOliveira ML and
Graf R: Strategies for safer liver surgery and partial liver
transplantation. N Engl J Med. 356:1545–1559. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brunocilla PR, Brunello F, Carucci P, et
al: Sorafenib in hepatocellular carcinoma: prospective study on
adverse events, quality of life, and related feasibility under
daily conditions. Med Oncol. 30:3452013. View Article : Google Scholar
|
|
4
|
Pawlik TM, Reyes DK, Cosgrove D, Kamel IR,
Bhagat N and Geschwind JF: Phase II trial of sorafenib combined
with concurrent transarterial chemoembolization with drug-eluting
beads for hepatocellular carcinoma. J Clin Oncol. 29:3960–3967.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vasievich EA and Huang L: The suppressive
tumor microenvironment: a challenge in cancer immunotherapy. Mol
Pharm. 8:635–641. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pardee AD and Butterfield LH:
Immunotherapy of hepatocellular carcinoma: unique challenges and
clinical opportunities. Oncoimmunology. 1:48–55. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ormandy LA, Farber A, Cantz T, et al:
Direct ex vivo analysis of dendritic cells in patients with
hepatocellular carcinoma. World J Gastroenterol. 12:3275–3282.
2006.
|
|
8
|
Hoechst B, Voigtlaender T, Ormandy L, et
al: Myeloid derived suppressor cells inhibit natural killer cells
in patients with hepatocellular carcinoma via the NKp30 receptor.
Hepatology. 50:799–807. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Teitz-Tennenbaum S, Li Q, Okuyama R, et
al: Mechanisms involved in radiation enhancement of intratumoral
dendritic cell therapy. J Immunother. 31:345–358. 2008. View Article : Google Scholar
|
|
10
|
Krusch M, Salih J, Schlicke M, et al: The
kinase inhibitors sunitinib and sorafenib differentially affect NK
cell antitumor reactivity in vitro. J Immunol. 183:8286–8294. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang QB, Sun HC, Zhang KZ, et al:
Suppression of natural killer cells by sorafenib contributes to
prometastatic effects in hepatocellular carcinoma. PLoS One.
8:e559452013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu Y, Li CS and Dong Q: Chinese herb
related molecules of cancer-cell-apoptosis: a minireview of
progress between Kanglaite injection and related genes. J Exp Clin
Cancer Res. 27:312008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhan YP, Huang XE, Cao J, et al: Clinical
safety and efficacy of Kanglaite® (Coix Seed Oil) injection
combined with chemotherapy in treating patients with gastric
cancer. Asian Pac J Cancer Prev. 13:5319–5321. 2012.
|
|
14
|
Pan P, Wu Y, Guo ZY, Wang R, Wang YJ and
Yuan YF: Antitumor activity and immunomodulatory effects of the
intraperitoneal administration of Kanglaite in vivo in Lewis lung
carcinoma. J Ethnopharmacol. 143:680–685. 2012. View Article : Google Scholar
|
|
15
|
Wullaert A, Bonnet MC and Pasparakis M:
NF-κB in the regulation of epithelial homeostasis and inflammation.
Cell Res. 21:146–158. 2011.
|
|
16
|
Porta C, Larghi P, Rimoldi M, et al:
Cellular and molecular pathways linking inflammation and cancer.
Immunobiology. 214:761–777. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Y, Yu G, Wang D, Hu Y and Lei W:
ERK1/2 activation plays important roles in the opposite effects of
Trichostatin A in non-cancer and cancer cells. Toxicon. 57:932–937.
2011. View Article : Google Scholar
|
|
18
|
Lee S, Ra J, Song JY, et al: Extracts from
Citrus unshiu promote immune-mediated inhibition of tumor
growth in a murine renal cell carcinoma model. J Ethnopharmacol.
133:973–979. 2011.
|
|
19
|
Wang J, Tong X, Li P, Cao H and Su W:
Immuno-enhancement effects of shenqi fuzheng injection on
cyclophosphamide-induced immunosuppression in Balb/c mice. J
Ethnopharmacol. 139:788–795. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang H, Hao S, Li F, Ye Z, Yang J and
Xiang J: CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory
response, tumor localization and therapy by targeted delivery of
interleukin 2 via acquired pMHC I complexes. Immunology.
120:148–159. 2007. View Article : Google Scholar
|
|
21
|
Rakhra K, Bachireddy P, Zabuawala T, et
al: CD4+ T cells contribute to the remodeling of the
microenvironment required for sustained tumor regression upon
oncogene inactivation. Cancer Cell. 18:485–498. 2010.
|
|
22
|
Chaput N, Darrasse-Jeze G, Bergot AS, et
al: Regulatory T cells prevent CD8 T cell maturation by inhibiting
CD4 Th cells at tumor sites. J Immunol. 179:4969–4978. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Biswas K, Richmond A, Rayman P, et al: GM2
expression in renal cell carcinoma: potential role in tumor-induced
T-cell dysfunction. Cancer Res. 66:6816–6825. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cui G and Florholmen J: Polarization of
cytokine profile from Th1 into Th2 along colorectal
adenoma-carcinoma sequence: implications for the biotherapeutic
target? Inflamm Allergy Drug Targets. 7:94–97. 2008. View Article : Google Scholar
|
|
25
|
Grimm M, Gasser M, Bueter M, et al:
Evaluation of immunological escape mechanisms in a mouse model of
colorectal liver metastases. BMC Cancer. 10:822010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baldwin AS: Regulation of cell death and
autophagy by IKK and NF-κB: critical mechanisms in immune function
and cancer. Immunol Rev. 246:327–345. 2012.
|
|
27
|
Shi Y, Feng Y, Kang J, et al: Critical
regulation of CD4+ T cell survival and autoimmunity by
β-arrestin 1. Nat Immunol. 8:817–824. 2007.
|
|
28
|
Weil R and Israel A: T-cell-receptor- and
B-cell-receptor-mediated activation of NF-kappaB in lymphocytes.
Curr Opin Immunol. 16:374–381. 2004. View Article : Google Scholar : PubMed/NCBI
|
